Mitochondrial DNA and fatigue
Recruiting
- Conditions
- Testicular germ-cell cancer, cancer-related fatigue, mitochondrial DNA, bleomycin, etoposide, cisplatin, BEP-chemotherapyTestiscarcinoom, kanker gerelateerde vermoeidheid, mitochondriaal DNA, bleomycine, etoposide, cisplatine, BEP-chemotherapie
- Registration Number
- NL-OMON22518
- Lead Sponsor
- Erasmus MC Cancer Institute, department of Medical Oncology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 37
Inclusion Criteria
Planned to receive three cycles of chemotherapy (bleomycin, etoposide, cisplatin) for metastatic testicular cancer
- Age of 18 years or older
Exclusion Criteria
- Cognitive impairments (i.e. inability to understand patient information leaflet or fatigue
questionnaires)
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine whether chemotherapy for metastatic germ cell cancer of the testis<br>(bleomycin/etoposide/cisplatin) induces changes in mtDNA of non-cancer cells that persist after completion of chemotherapy. This will give indirect information on possible impairment of mitochondrial functioning.
- Secondary Outcome Measures
Name Time Method - To determine whether persistent mitochondrial impairment is observed in these non-cancer cells.<br /><br>- To determine the severity of fatigue before, during and after the chemotherapy cycles and its relation with the occurrence of changes in mtDNA in non-cancer cells.